Germline BRCA mutations have an adverse impact on both progression-free and overall survival in patients with hormone receptor-positive/HER2-negative metastatic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...
An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Epigenetic and genetic alterations of DYPD in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer. Background: Breast cancer patients' carriers of germline mutations of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback